Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHA) Total Non-Current Liabilities (2017 - 2025)

Historic Total Non-Current Liabilities for Innate Pharma (IPHA) over the last 9 years, with Q2 2025 value amounting to $66.1 million.

  • Innate Pharma's Total Non-Current Liabilities fell 2737.53% to $66.1 million in Q2 2025 from the same period last year, while for Jun 2025 it was $66.1 million, marking a year-over-year decrease of 2737.53%. This contributed to the annual value of $74.0 million for FY2024, which is 1778.68% down from last year.
  • Innate Pharma's Total Non-Current Liabilities amounted to $66.1 million in Q2 2025, which was down 2737.53% from $74.0 million recorded in Q4 2024.
  • Over the past 5 years, Innate Pharma's Total Non-Current Liabilities peaked at $112.7 million during Q2 2023, and registered a low of $66.1 million during Q2 2025.
  • Moreover, its 5-year median value for Total Non-Current Liabilities was $91.7 million (2021), whereas its average is $92.9 million.
  • Per our database at Business Quant, Innate Pharma's Total Non-Current Liabilities crashed by 9974.76% in 2021 and then soared by 1668.1% in 2023.
  • Quarter analysis of 5 years shows Innate Pharma's Total Non-Current Liabilities stood at $91.7 million in 2021, then grew by 15.48% to $105.9 million in 2022, then fell by 15.02% to $90.0 million in 2023, then decreased by 17.79% to $74.0 million in 2024, then decreased by 10.71% to $66.1 million in 2025.
  • Its Total Non-Current Liabilities stands at $66.1 million for Q2 2025, versus $74.0 million for Q4 2024 and $91.0 million for Q2 2024.